TY - JOUR
T1 - A bioinspired hyperthermic macrophage-based polypyrrole-polyethylenimine (Ppy-PEI) nanocomplex carrier to prevent and disrupt thrombotic fibrin clots
AU - Burnouf, Thierry
AU - Chen, Chih Hwa
AU - Tan, Shun Jen
AU - Tseng, Ching Li
AU - Lu, Kun Ying
AU - Chang, Lee Hsin
AU - Nyambat, Batzaya
AU - Huang, Shao Chan
AU - Jheng, Pei Ru
AU - Aditya, Robby Nur
AU - Mi, Fwu Long
AU - Chuang, Er Yuan
N1 - Funding Information:
T.B. C.H.C. and S.J.T. contributed equally to this study. This work was financially supported by Ministry of Science and Technology, Taiwan, through grant number 106-2314-B-038-022-MY2 and Taipei Medical University Hospital grant107TMU-TMUH-01. T.B. C.H.C. S.J.T, E.-Y.C. and F.-L.M. designed the research, gathered the experimental data and contributed materials or investigative tools. K.-Y.L. and P.R.J. conducted the examination of materials, flow cytometry, CLSM, and in vitro analyses. E.-Y.C. and L.-H. C. assisted with the ex vivo anti-thrombosis experiment. C.L.T. B.N. S.C.H. P.R.J. and R.N. assisted with experiments including Zetasizer, CLSM, IVIS, and histology. C.H.C. and S.J.T. provided clinical suggestions. T.B. C.H.C. S.J.T. E.-Y.C. and F.-L.M. discussed the outcomes and wrote the manuscript. All authors reviewed the manuscript and provided comments. We thank Uni-edit (www.uni-edit.net) for editing and proofreading this manuscript. This study has been filed for Taiwanese patent. The authors declare no conflicts of interest.
Funding Information:
T.B., C.H.C. and S.J.T. contributed equally to this study. This work was financially supported by Ministry of Science and Technology, Taiwan , through grant number 106-2314-B-038-022-MY2 and Taipei Medical University Hospital grant107TMU-TMUH-01. T.B., C.H.C., S.J.T, E.-Y.C. and F.-L.M. designed the research, gathered the experimental data and contributed materials or investigative tools. K.-Y.L. and P.R.J. conducted the examination of materials, flow cytometry, CLSM , and in vitro analyses. E.-Y.C. and L.-H. C. assisted with the ex vivo anti-thrombosis experiment. C.L.T., B.N., S.C.H., P.R.J. and R.N. assisted with experiments including Zetasizer, CLSM, IVIS, and histology. C.H.C. and S.J.T. provided clinical suggestions. T.B., C.H.C., S.J.T., E.-Y.C. and F.-L.M. discussed the outcomes and wrote the manuscript. All authors reviewed the manuscript and provided comments. We thank Uni-edit ( www.uni-edit.net ) for editing and proofreading this manuscript.
Publisher Copyright:
© 2019
PY - 2019/9/15
Y1 - 2019/9/15
N2 - Fibrinolytic treatments for venous or arterial thrombotic syndromes using systemic administration of thrombolytics, such as streptokinase, can induce life-threatening bleeding complications. In this study, we offer the first proof of concept for a targeted photothermal fibrin clot prevention and reduction technology using macrophages loaded with polypyrrole-polyethylenimine nanocomplexes (Ppy-PEI NCs) and subjected to near-infrared radiation (NIR). We first show that the developed Ppy-PEI NCs could be taken up by defensive macrophages in vitro through endocytosis. The Ppy-PEI NCs generated local hyperthermia upon NIR treatment, which appeared to produce reactive oxygen species in Ppy-PEI NC-loaded macrophages. Preliminary evidence of efficacy as an antithrombotic tool is provided, in vitro, using fibrinogen-converted fibrin clots, and in vivo, in a rat femoral vascular thrombosis model generated by exposure to ferric chloride substance. The in vivo biocompatibility, photothermal behavior, biodistribution, and histological observation of cellular interactions with the Ppy-PEI NCs in the rat model provide rationale in support of further preclinical studies. This Ppy-PEI NC/NIR-based method, which uses a unique macrophage-guided targeting approach to prevent and lyse fibrin clots, may potentially overcome some of the disadvantages of current thrombolytic treatments. Statement of Significance: Fibrinolytic treatments for venous or arterial thrombotic syndromes using systemic administration of thrombolytics, such as streptokinase, can induce life-threatening bleeding complications. In this study, we offer the first proof of concept for a targeted photothermal fibrin clot reduction technology using macrophages loaded with polypyrrole-polyethylenimine nanocomplexes (Ppy-PEI NCs) and subjected to near-infrared radiation (NIR). We first show that the developed Ppy-PEI NCs can be taken up by defensive macrophages in vitro through endocytosis. The Ppy-PEI NCs generated local hyperthermia upon NIR treatment, which appeared to produce reactive oxygen species in Ppy-PEI NC-loaded macrophages. Preliminary evidence of efficacy as an antithrombotic tool is provided, in vitro, using fibrinogen-converted fibrin clots, and in vivo, in a rat femoral vascular thrombosis model generated by exposure to ferric chloride substance. The in vivo biocompatibility, photothermal behavior, biodistribution, and histological observation of cellular interactions with the Ppy-PEI NCs in the rat model provide rationale in support of further preclinical studies. This Ppy-PEI NC/NIR-based method, which uses a unique macrophage-guided targeting approach to disintegrate fibrin clots, may potentially overcome some of the disadvantages of current thrombolytic treatments.
AB - Fibrinolytic treatments for venous or arterial thrombotic syndromes using systemic administration of thrombolytics, such as streptokinase, can induce life-threatening bleeding complications. In this study, we offer the first proof of concept for a targeted photothermal fibrin clot prevention and reduction technology using macrophages loaded with polypyrrole-polyethylenimine nanocomplexes (Ppy-PEI NCs) and subjected to near-infrared radiation (NIR). We first show that the developed Ppy-PEI NCs could be taken up by defensive macrophages in vitro through endocytosis. The Ppy-PEI NCs generated local hyperthermia upon NIR treatment, which appeared to produce reactive oxygen species in Ppy-PEI NC-loaded macrophages. Preliminary evidence of efficacy as an antithrombotic tool is provided, in vitro, using fibrinogen-converted fibrin clots, and in vivo, in a rat femoral vascular thrombosis model generated by exposure to ferric chloride substance. The in vivo biocompatibility, photothermal behavior, biodistribution, and histological observation of cellular interactions with the Ppy-PEI NCs in the rat model provide rationale in support of further preclinical studies. This Ppy-PEI NC/NIR-based method, which uses a unique macrophage-guided targeting approach to prevent and lyse fibrin clots, may potentially overcome some of the disadvantages of current thrombolytic treatments. Statement of Significance: Fibrinolytic treatments for venous or arterial thrombotic syndromes using systemic administration of thrombolytics, such as streptokinase, can induce life-threatening bleeding complications. In this study, we offer the first proof of concept for a targeted photothermal fibrin clot reduction technology using macrophages loaded with polypyrrole-polyethylenimine nanocomplexes (Ppy-PEI NCs) and subjected to near-infrared radiation (NIR). We first show that the developed Ppy-PEI NCs can be taken up by defensive macrophages in vitro through endocytosis. The Ppy-PEI NCs generated local hyperthermia upon NIR treatment, which appeared to produce reactive oxygen species in Ppy-PEI NC-loaded macrophages. Preliminary evidence of efficacy as an antithrombotic tool is provided, in vitro, using fibrinogen-converted fibrin clots, and in vivo, in a rat femoral vascular thrombosis model generated by exposure to ferric chloride substance. The in vivo biocompatibility, photothermal behavior, biodistribution, and histological observation of cellular interactions with the Ppy-PEI NCs in the rat model provide rationale in support of further preclinical studies. This Ppy-PEI NC/NIR-based method, which uses a unique macrophage-guided targeting approach to disintegrate fibrin clots, may potentially overcome some of the disadvantages of current thrombolytic treatments.
KW - Macrophage
KW - Photothermal effect
KW - Ppy-PEI NC
KW - ROS
KW - Thrombolytic therapy
UR - http://www.scopus.com/inward/record.url?scp=85068266126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068266126&partnerID=8YFLogxK
U2 - 10.1016/j.actbio.2019.06.053
DO - 10.1016/j.actbio.2019.06.053
M3 - Article
AN - SCOPUS:85068266126
SN - 1742-7061
VL - 96
SP - 468
EP - 479
JO - Acta Biomaterialia
JF - Acta Biomaterialia
ER -